Monoclonal antibodies 14.18 (IgG3) and 11C64 (IgG3) directed against disialogangliosides GD2 and GD3, respectively, when used in conjunction with human peripheral blood mononuclear cells (PBMCs) stimulated with human recombinant interleukin (rIL-2) lyse both human melanoma and neuroblastoma cells by antibody-dependent cellular cytotoxicity. Such monoclonal antibody-"armed" effector cells are specifically directed to targets expressing the given disialoganglioside without detectable cross-reactivity. In addition, antibody-dependent cellular cytotoxicity as well as the natural killing ability of human PBMCs is augmented by a brief coincubation with rIL-2. PBMCs augmented by rIL-2 and armed with monoclonal antibodies significantly suppressed tumor growth in the xenotransplant nude mouse model. Our results suggest that once a threshold level of activation of PBMCs is achieved, additional rIL-2 (over three orders of magnitude of concentration) does not significantly enhance cytolytic augmentation. Furthermore, anti-GD3 monoclonal antibody 11C64 together with rIL-2-stimulated PBMCs from melanoma patients with widely differing tumor burdens effectively lyse melanoma tumor targets in antibody-dependent cellular cytotoxicity. Our results also suggest that GD2 and GD3 represent distinct and relevant immunotherapeutic target structures on melanoma whereas GD2 does the same for neuroblastoma tumors. Our data suggest that targeting of activated human effector cells may provide a new and effective cancer immunotherapy protocol.
Gangliosides (sialic acid bearing glycolipids) are rapidly being characterized as tumor markers that are relevant target antigens for monoclonal antibody (mAb)-mediated immunotherapy (1) (2) (3) (4) (5) (6) (7) . The disialoganglioside GD3, expressed preferentially on human melanoma cells (8) (9) (10) , is an effective target in vitro for both complement-mediated tumor cytolysis and antibody-dependent cellular cytoxicity (ADCC) by mAbs ofthe IgG3 subclass (3) (4) (5) 7) . [Gangliosides (e.g., GD2 and GD3) are designated according to the nomenclature of Svennerholm (11) .] We and others also reported that mAbs (IgG3) directed against GD3 could effectively suppress the establishment of human melanoma tumors in the xenotransplant nude mouse model (3, 4) . We reported that murine mononuclear splenocytes "armed" with anti-GD3 mAb could eradicate well-established and progressively growing human melanoma tumors in nude mice (5, 7) . Additionally, Houghton et al. (2) , using mAb R24 (IgG3) directed to GD3, observed major tumor regressions in 3 of 11 melanoma patients treated with this antibody in a phase I clinical trial. These findings demonstrate that the potential therapeutic efficacy of anti-GD3 mAbs warrants further study of gangliosides as immunotherapeutic targets.
Another form of anti-tumor immunotherapy involves the exposure of mononuclear lymphocytes to the lymphokine interleukin 2 (IL-2) to generate lymphokine-activated killer (LAK) cells (12) (13) (14) (15) . Thus, Rosenberg et al. (16) 
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mAbs. mAbs 14.18 (IgG3) and 11C64 (IgG3) directed against disialoganglioside GD2 and GD3, respectively, were produced in our laboratory; J606 (IgG3), anti-levan and inulin was kindly provided by M. Cohn (Salk Institute). These mAbs were purified by salting out and affinity chromatography using protein A-Sepharose (Pharmacia Fine Chemicals, Uppsala, Sweden) (17) . The collected fractions were extensively dialyzed against a 0.1 M citrate buffer, pH 6.7, containing 5% (wt/vol) sucrose. The purified mAbs were stored at -700C, and their activity was assessed with an ELISA assay as described (10) . The purity and stability of the mAb preparations was evident from sedimentation-velocity analysis, performed with a Beckman model E ultracentrifuge, that revealed a monomeric 7S protein (18 (20) . These cells were added to microtiter wells at the indicated effector/target (E/T) cell ratios, and the plate was incubated for 4 hr at 37°C and processed as described (4 GD2 and GD3, and the neuroblastoma cell line SK-N-AS, which is GD2 positive and GD3 negative, were each labeled with 51Cr and used as target cells. Three mAbs of the IgG3 subclass were used to target human PBMCs, i.e., 11C64 (anti-GD3), 14.18 (anti-GD2), and J606 (anti-levan and -inulin). As shown in Table 1 , the effector cells armed with mAbs directed against GD3 and GD2 exhibit exquisite specificity for their respective targets, whereas the control mAb J606 is nonreactive. Addition of rIL-2 (500 units/ml) does not create a nonspecific enhancement by these armed effector cell populations. Background lysis induced by incubation of rIL-2 with target cells alone was routinely less than 2%.
NK and ADCC Cytolytic Activity Is Enhanced by Low Doses of To analyze the potentiation of lytic activity of PBMCs of two independent donors, rIL-2 was added to the 4-hr ADCC assay at doses ranging from 50 to 50,000 units/ml. We selected the minimum dose of 50 units since lower concentrations of rIL-2 proved ineffective on PBMCs. From these donors, an almost identical degree of enhancement in lytic activity was observed over a range of three orders of magnitude when rIL-2 from 50 to 50,000 units/ml was added to the ADCC assay in combination with mAb 11C64 (Table ADCC was mediated by mAbs 11C64 (anti-GD3) and 14.18 (anti-GD2) and normal human effector cells on human melanoma and neuroblastoma target cells. The effector/target cell ratios of 100:1, 50:1, and 25:1 are indicated as 100, 50, and 25. The percentage of specific lysis was determined on 51Cr-labeled targets in the presence or absence of rIL-2 during a 4-hr assay. *The concentration of mAb was 25 ug/ml, and the amount of rIL-2 was 500 units/ml.
2). In the case of donor 1, at an E/T cell ratio of 25:1, the increase in NK lysis induced by rIL-2 ranged from 4% to 8%. Lysis obtained by PBMCs and mAb 11C64 was 16%, whereas the combined modality (PBMCs, rIL-2, and mAb 11C64) produced lytic values ranging from 35% to 42%. These results are noteworthy since the combined modality produced a net mean lysis of 38%, i.e., approximately a 100% increase over armed effector cells without rIL-2. This synergism for donor 1 was repeated in two additional experiments. In this same study, donor 2 exhibited the same cytolytic reactivity over the three orders of magnitude of rIL-2 concentration similar to those levels observed for donor 1.
Cytolytic Enhancement of Human Mononuclear Cells by rIL-2. ADCC experiments indicated that at a relatively high E/T cell ratio of 100:1, coincubation of PBMCs and rIL-2 for either 15 min or 4 hr resulted in comparable levels of mAb-directed killing in the ADCC assay-95.5% and 93.4%, respectively. mAb 11C64-directed killing in the absence of rIL-2 was 75% (Fig. 1) . Examination of this cytolytic enhancement at a lower E/T cell ratio of 25:1 again revealed that lytic activation occurs rapidly. Specifically, ADCC lytic activity increased from 24% to 44% in 30 min and continued to rise throughout the duration of the 4-hr coincubation up to (Fig. 1) . In the following experiments, PBMCs were coincubated for 4 hr with rIL-2 (500 units/ml), thoroughly washed free of rIL-2, and maintained for 20 hr in the absence of rIL-2 in DMEM and 10% (vol/vol) fetal calf serum at 37°C in a 7.5% C02/92.5% air humidified atmosphere. The lytic activity was then assessed in the ADCC assay by comparing the respective efficacies of the same donor's PBMCs incubated under similar conditions for 24 hr without rIL-2, or of fresh PBMCs obtained the day of the assay from the same donor. Table 3 reveals that a 4-hr coincubation of PBMCs and rIL-2 (500 units/ml) followed by the removal of rIL-2 for 20 hr resulted in augmented lytic activity (NK lysis of 77%; mAb 11C64-directed killing of 82.7%). This lytic activation is maintained and is comparable to that generated by PBMCs continuously exposed to rIL-2 for 24 hr (NK lysis of 76%; mAb 11C64-directed killing of 80%). The control values obtained for the overnight incubations were NK lysis of 13% and mAb 11C64-directed killing of 64.6%.
The Cytolytic Activity of Melanoma Patients' Mononuclear Cells Is Enhanced by a Brief Coincubation with rIL-2. To assess the responsiveness of such a protocol with melanoma patients, PBMCs were obtained from four patients that differed in their stage of disease, i.e., showed markedly different tumor burdens. At an E/T cell ratio of 100:1, melanoma patients' PBMCs and mAb 11C64 induced lysis ranging from 24% to 73%. When melanoma patients' PBMCs were coincubated with rIL-2 for the duration of the 4-hr assay, the induced lysis ranged from 18% to 39%. Finally, coincubation of melanoma patients' PBMCs with rIL-2 and mAb 11C64 induced lysis that ranged from 48% to 88%. In these same experiments, normal control values were 30% for 
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DISCUSSION
We have demonstrated that a brief coincubation of human rIL-2 with human peripheral blood mononuclear effector cells potently augments both natural killing and ADCCmediated cytolysis of human melanoma cells in vitro and in vivo. We chose to call these effector cells LAK cells, although we did not incubate the PBMCs for the prolonged time periods described by others (12) (13) (14) (15) (16) . Alternatively, these effector cells could be regarded as augmented killer or NK cells, since we showed such cells to be effective in ADCC (7) . The results presented here were obtained with PBMCs from 20 different donors and were analyzed in over 60 independent ADCC assays. In all cases examined, the results clearly and uniformly demonstrated that a low dose and a brief exposure of human PBMCs to rIL-2 augments both natural killing and ADCC-mediated cytolysis of human melanoma and neuroblastoma target cells. We also showed that mAbs 14.18 (anti-GD2) and 11C64 (anti-GD3) effectively armed effector cells that are specifically directed to their respective targets, either with or without rIL-2-induced augmentation. Additionally, the same experimental protocol employing rIL-2 that augments natural killing and ADCC was also effective with PBMCs obtained from melanoma patients. It is noteworthy that a similar level of cytolytic augmentation of PBMCs was induced by rIL-2 over a dose range of three orders of magnitude, suggesting that once a threshold level of activation is achieved, it is not further enhanced by additional rIL-2.
An interesting observation made during this study with PBMCs from 20 different donors was the wide-ranging ADCC activity observed among donors, whereas the relative level of ADCC activity of an individual donor remained internally consistent. Although we have observed differences in rIL-2-induced augmentation of ADCC activity between different donors, an individual donor's PBMCs repeatedly exhibited a reproducible pattern. In some cases, we observed a clear synergism whenever the combined modality of rIL-2 and mAb was employed. In other cases the rIL-2-induced ADCC augmentation appears more like an additive effect of combining the net cytolysis of rIL-2-induced natural killing with independently generated killing by ADCC in the absence of rIL-2. The duration of lytic activation maintained in the absence of rIL-2 can also vary among individual donors. However, activation data obtained with rIL-2-augmented PBMCs suggest that once the effector cells of some donors are activated and then depleted of rIL-2, they continue to (22) reported that a 2-to 4-hr exposure to IL-2 markedly enhances the cytolytic activity of heteroconjugate mAb-targeted human peripheral T cells. These data and our previous observations of armed murine effector cells that effectively eradicated established melanoma xenotransplants in the athymic mouse (5, 7) provide a working rationale for designing and optimizing new treatment protocols for melanoma and neuroblastoma patients, and possibly for other tumors of neuroectodermal origin expressing disialoganglioside tumor antigens. In this case, human PBMC effector cells would be briefly activated ex vivo with relatively low doses of rIL-2, followed by a short coincubation with mAbs directed to GD2 and/or GD3 to further arm and then target such cells to melanoma tumors or other tumors of neuroectodermal origin. As indicated in Table 4 , our preliminary in vivo observations in the xenotransplant nude mouse model are particularly encouraging since they indicate that human PBMCs subjected to this treatment can effectively suppress the growth of established human melanoma tumors in nude mice. It is, of course, quite apparent that considerably more work has to be done in this model system to optimize this potential immunotherapeutic treatment modality before it can be critically evaluated in clinical trials.
